Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high113.00 03/05/16
52 week low60.00 31/03/17
52 week change -22.50 (-20.00%)
4 week volume931,779 01/04/17

Media for (AVCT)

Presenter: Dr. Alastair Smith
01/08/2014
Presenter: Dr. Alastair Smith
07/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Avacta agrees exclusive deal with global diagnostics firm

Avacta Group has confirmed that an evaluation of its Affimer technology by a large, global diagnostics developer has con...

Diagnostics firm take rights to several Affimers

RNS Number: 0419D Avacta Group PLC 24 April 2017 24 April 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Top three global diagnostics company takes exclusive rights to several Affimer reagents Important value inflection point validating commercial potential of Affimer technology and Company's business model Avacta Group plc (AIM: ...

Avacta to present at Shares Spotlight Evening

Avacta chief executive Alastair Smith will be presenting at the Shares Spotlight Evening on 26 April at the Novotel Hotel, T...

Avacta to Present at the Shares Spotlight Evening

RNS Number: 6213C Avacta Group PLC 19 April 2017 19 April 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present at the Shares Spotlight Evening Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the ...

Hardman Research: Another important box ticked

RNS Number: 2542C Avacta Group PLC 12 April 2017 Hardman Research: Another important box ticked Another important box ticked: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates th...

Holding(s) in Company

RNS Number: 8339B Avacta Group PLC 06 April 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Avacta Group PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition...

Holding(s) in Company

RNS Number: 8336B Avacta Group PLC 06 April 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Avacta Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition o...

Director/PDMR Shareholding

RNS Number: 7956B Avacta Group PLC 06 April 2017 06 April 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director Dealing and Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 5,731 new ordinary shares of 10p each (the "New Ord...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Equity Research (AVCT)

hardman & co
Avacta Group Plc
12/04/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
21/03/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
02/11/2016
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...

Latest discussion posts More

  • Re: Tonight's presentation slides

    of particular note FY17 forecast c.#1.2m revenues from paid-for evaluations and customised Affimer generation compared to half year 17 Half year revenues increased ...
    26-Apr-2017
    mol42
  • Tonight's presentation slides

    available prior to presentation tonight http://www.avacta.com/sites/life_sciences/files/resource/Avacta%20Group%20Shares%20Evening%20April%2026.pdf we're getting better ...
    26-Apr-2017
    mol42
  • A Smith Interview 250417

    http://www.proactiveinvestors.co.uk/companies/stocktube/7332/avacta-ceo-dr-alastair-smith-encouraged-by-first-commercial-affimer-deal-7332.html mol
    25-Apr-2017
    mol42

Users' HoldingsMore

Users who hold Avacta Group also hold..
LLOYDS GRP.21%
ROCKHOPPER17%
BARCLAYS12%
Matra Petroleum AB ORD SEK0.00111%
ROYAL BANK SCOT11%

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT